Page 13 - சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Adding a year of CDK4/6 inhibition to adjuvant endocrine therapy failed to improve invasive disease-free survival (iDFS) in early hormone receptor (HR)-positive breast cancer patients who had residual disease following neoadjuvant chemotherapy, a phase III trial showed. In the PENELOPE-B study of over 1,200 patients, no difference in the primary endpoint of iDFS was observed between the group receiving palbociclib (Ibrance) and those assigned to placebo, after a median follow-up of 43 months (stratified HR 0.93, 95% CI 0.74-1.17, P=0.525), reported Sibylle Loibl, MD, PhD, of the German Breast Group. The addition of 1 year of palbociclib to endocrine therapy in patients with hormone receptor-positive/HER2-negative breast cancer and at high risk of relapse after neoadjuvant chemotherapy does not improve invasive disease-free survival, she said during her presentation at the virtual San Antonio Breast Cancer Symposium (SABCS). No group could be identified wit

San antonioUnited statesRuth oreganIan ingramUniversity of wisconsinGerman breast groupSibylle loiblGerman breastSan antonio breast cancer symposiumRutho reganMedpage todayDeputy managing editorAntonio breast cancerசான் அன்டோனியோஒன்றுபட்டது மாநிலங்களில்ரூத் ஒரேகன்